• Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs

    29 days ago - By San Diego Biotechnology

    Earlier this year, Avidity Biosciences and Eli Lilly began a partnership to develop new drugs based on the biotech's technology for delivering genetic material to cells. On Wednesday, Lilly was among a group of investors that joined a $100 million fina......
    Read more ...

     

  • Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs

    Avidity Bio Adds $100M to Advance R&D of Muscle Disorder Drugs

    29 days ago - By Xconomy

    Earlier this year, Avidity Biosciences and Eli Lilly began a partnership to develop new drugs based on the biotech's technology for delivering genetic material to cells. On Wednesday, Lilly was among a group of investors that joined a $100 million financing for the company. The funding, a Series C round , was led by RTW Investments. La Jolla, CA-based Avidity is developing drugs called antibody-oligonucleotide conjugates. These drugs employ the tissue-targeting properties of an antibody, using it to carry a therapeutic payload of modified RNA called an oligonucleotide. The company says...
    Read more ...